Tesamorelin 20
A growth-hormone-releasing factor analogue in a 20 mg pen, studied for visceral-fat research. Each click delivers 67 µg from a 3 mL · 300-click pen.
Featured in these stacks: Muscle Growth, Advanced Lean Stack.
how many clicks
for your dose?
This Tesamorelin 20 pen holds 20 mg across 300 clicks, so each click delivers 67 µg. Tap a dose or turn the dial; we'll count the clicks. For research reference only.
why researchers chose this pen
chose it for the click dosing, no syringes, no unit maths.
verified purity, checked against the public CoA before first use.
precise clicks in every 3 mL pen, the whole protocol in one barrel.
re-order or refer a colleague within three months.
about the
Tesamorelin 20 pen
Tesamorelin is a stabilised growth-hormone-releasing-hormone analogue, supplied in a 3 mL / 300-click pen for research.
Certificate of analysiswhy a pen beats
a vial & syringe
Traditional research peptides arrive as lyophilised powder that must be reconstituted, drawn into insulin syringes, and converted from milligrams to units by hand, every step a chance for a dosing error.
A multi-dose pen removes the whole failure chain. The peptide arrives already dissolved and calibrated. Attach a fresh needle, turn the dial until you count your clicks, and you're done, the same audible-click mechanism trusted in insulin and GLP-1 pens worldwide.
Pens travel and store better, too: no open vials, no bent needles, no septum contamination after repeated draws. One sealed barrel, ten sterile needles, one dosing card.
how to buy
peptides safely
The peptide market has a purity problem: independent surveys routinely find underdosed, mislabelled or contaminated product sold online. The only reliable defence is third-party verification you can check yourself, not a supplier's own claims.
Before buying any peptide pen, ask three questions. Is every batch tested by an independent lab? Is the certificate of analysis available, so you can check your exact lot before first use? And does it ship cold-chain, insulated and gel-packed, so what was tested is what arrives?
Veyvora answers yes on every order, independent assay, a CoA on request against the batch number, and cold dispatch within 24 hours, paperwork packed inside.
pairs well with
view all
Overview
The Veyvora Tesamorelin 20 mg Research Pen is a 3 mL pre-filled multi-dose pen containing 20 mg of tesamorelin across 300 clicks, supplied strictly for in-vitro laboratory research use. Each pen is batch-numbered, sealed, and dispatched cold within 24 hours with a certificate of analysis (CoA) available on request [1]. Current GBP pricing is not shown in publicly captured page content and should be confirmed at checkout [3].
| Specification | Detail |
|---|---|
| Total peptide content | 20 mg |
| Fill volume | 3 mL |
| Clicks per pen | 300 |
| Delivery per click | ~67 µg |
| Included accessories | 10 × 31G 6 mm pen needles |
| Documentation | Batch-specific CoA on request |
Availability: Active product page; ships to the United Kingdom [1][5]. Add to basket: Confirm current price and stock at veyvora.com/peptides/tesamorelin-20.
Each pen delivers approximately 67 µg per click across 300 clicks and ships with a batch-specific CoA available on request, for laboratory research use only (Veyvora, 2026) [1].
Product Identity and Scope
Veyvora supplies the Tesamorelin 20 mg Research Pen as a 3 mL pre-filled multi-dose pen, batch-numbered on the barrel, strictly for in-vitro laboratory research use. The pen is not a medicine and carries no authorisation for human or veterinary use (Veyvora, 2026) [1][2].
Veyvora describes tesamorelin as a stabilised growth-hormone-releasing hormone (GHRH) analogue and positions the pen within visceral-fat and growth-hormone-axis research programmes [1][2]. The product page closes with the statement “For research reference only”, consistent with the site-wide disclaimer that all peptides are supplied for laboratory research use only and are not medicines [1][2]. Researchers receiving a unit should verify their batch against its CoA before first use, since the barrel batch number is the controlling link between the physical pen and its documentation.
For UK context, the European Medicines Agency (EMA) record confirms that the EU marketing-authorisation application for Egrifta (tesamorelin) was withdrawn on 21 June 2012, and no current EMA-authorised tesamorelin medicine exists [4]. No Medicines and Healthcare products Regulatory Agency (MHRA) marketing authorisation for tesamorelin is evidenced in the available sources [4][6].
Verified Specifications
Each click of the Tesamorelin 20 mg Research Pen delivers approximately 67 µg, the arithmetic result of 20 mg divided by 300, as stated in the product specification (Veyvora, 2026) [1]. Each unit ships with 10 × 31G 6 mm pen needles in the box [1].
| Specification | Value | Source |
|---|---|---|
| Total tesamorelin content | 20 mg | Veyvora, 2026 [1] |
| Fill volume | 3 mL | Veyvora, 2026 [1] |
| Clicks per pen | 300 | Veyvora, 2026 [1] |
| Delivery per click | ~67 µg | Veyvora, 2026 [1] |
| Needles included | 10 × 31G 6 mm | Veyvora, 2026 [1] |
| Excipient list | [operator confirmation required] | — |
| Amino-acid sequence | [operator confirmation required] | — |
Veyvora describes the pen as sealed and ready to prime, with the barrel batch number linking the physical unit to its CoA [1][2]. The product page does not publish a full excipient list, fill volume by mass, or amino-acid sequence in its publicly accessible text. Researchers requiring those values should request the batch-specific CoA or consult the tesamorelin research profile for compound background before ordering [1][2].
Batch Documentation and Analytical Evidence
Every Tesamorelin 20 mg Research Pen carries a batch number on the barrel, and Veyvora makes a CoA available on request, matched to that specific lot number [1][2]. The public product page does not name the testing laboratory, analytical methods, or numerical purity, endotoxin, or sterility values for any specific tesamorelin batch. Those figures remain unverified until a researcher reviews the CoA directly [1][2]. The marketing page alone does not support a batch-specific purity claim; the CoA is the controlling document for any such assertion.
Veyvora’s category pages state that each pen is independently assayed and that the CoA reports identity and high-performance liquid chromatography (HPLC) purity [2]. The specific lot result, detection limits, and endotoxin threshold are not published in the publicly accessible product text and should be treated as operator-confirmed values only once the batch document is in hand [1][2].
Researchers comparing formats across the Growth & Recovery research pens catalogue should request the CoA before placing an order, as batch-level analytical data forms the appropriate basis for any documentation review. For post-receipt handling considerations, including storage conditions that affect sample integrity, see Veyvora’s research-peptide storage and stability guidance.
Handling and Storage
Veyvora dispatches the Tesamorelin 20 mg Research Pen cold, packed in an insulated sleeve with an ice pack, and ships within 24 hours to the United Kingdom [3][5]. Order paperwork is included inside the parcel [1][3]. No formal stability window, beyond-use date, or specific storage temperature range appears in the publicly accessible product text, so those values should be confirmed on the batch CoA or the insert supplied with the order [1][3].
Storage conditions can vary by batch and fulfilment route, so the batch-specific insert and dispatch materials are the primary handling references for any given lot. Before first use, verify your batch against its CoA to confirm that the received pen matches the documented analytical result. To assess what HPLC purity data does and does not establish about sample integrity, see what HPLC purity does and does not prove.
Ordering Information
Veyvora lists the Tesamorelin 20 mg Research Pen as an active product dispatched to the United Kingdom, with cold shipping within 24 hours and order paperwork packed inside the parcel [1][3]. No current GBP price appears in the publicly accessible product pages captured as of 30 August 2026, so the purchase price should be confirmed directly at checkout before ordering [3]. Minimum order quantity, shipping fees, and live stock levels are not published in the available page content and must be confirmed with Veyvora at the point of purchase [1][3].
A CoA is available on request and matched to the batch number on the pen barrel, providing lot-level traceability between the physical unit and its documentation [1][2]. Researchers who need compound background before committing to an order can consult the tesamorelin research profile; those who need reference values for the pen format can refer to the tesamorelin dosing-card reference values.
Research-Use-Only Limitations
The Tesamorelin 20 mg Research Pen is supplied strictly for in-vitro laboratory research use only and is not a medicine, prescription product, or veterinary preparation [1][2]. Veyvora states this explicitly across its product and category pages, and the Tesamorelin 20 page closes with the notice “For research reference only” [1][3]. Researchers and prospective distributors should treat this classification as a hard boundary: the product page contains no dosing protocols, treatment directions, or human-outcome claims, and none should be inferred from the analytical documentation.
The regulatory position reinforces this. EMA records confirm that the EU marketing-authorisation application for Egrifta (tesamorelin) was withdrawn on 21 June 2012, meaning tesamorelin has never held EMA-authorised medicinal status, and no MHRA marketing authorisation for tesamorelin appears in the sources available here [4][7]. UK procurement must therefore remain within a laboratory research context; any implication of licensed medicinal availability in the United Kingdom is unsupported by the evidence [4][6].
For post-shipment handling within a research setting, research-peptide storage and stability guidance covers considerations beyond the dispatch summary on this page. Researchers comparing nearby formats in the same research category can browse the Growth & Recovery research pens catalogue [2].
Related Research and Comparison Pages
Veyvora positions the Tesamorelin 20 mg Research Pen within two distinct category ranges: the Growth & Recovery research pens catalogue, which groups tesamorelin alongside other GHRH-axis compounds and includes a head-to-head comparison page for this peptide class [2], and the Metabolic & Weight research pens range, which places tesamorelin alongside compounds such as tirzepatide and retatrutide, organised by receptor profile and research pathway rather than therapeutic indication [3]. Neither category page is independent evidence of product quality; they describe grouping logic only.
Before committing to a purchase, researchers should verify their batch against its CoA by matching the barrel lot number to the corresponding certificate of analysis. The batch document, not the product page, is the controlling source for purity and endotoxin values [1][2]. For a precise account of what HPLC data does and does not establish about peptide identity, what HPLC purity does and does not prove provides the methodological context without overloading this product listing.
To order the Tesamorelin 20 mg Research Pen for in-vitro laboratory use, visit the product page at veyvora.com/peptides/tesamorelin-20 and request the batch-specific CoA at checkout [1].
Sources
[1] Tesamorelin 20 mg Pen | Veyvora, veyvora.com, https://veyvora.com/peptides/tesamorelin-20 [2] Growth & Recovery Research Pens | Veyvora, veyvora.com, https://veyvora.com/categories/growth [3] Metabolic & Weight Research Pens | Veyvora, veyvora.com, https://veyvora.com/categories/metabolic [4] Egrifta | European Medicines Agency (EMA), ema.europa.eu, 2012, https://www.ema.europa.eu/en/medicines/human/EPAR/egrifta [5] Veyvora, research peptides, measured to the microgram, veyvora.com, https://veyvora.com/ [6] Tesamorelin (UK): GHRH analogue (EGRIFTA), no licence, peptideclear.co.uk, 2026, https://peptideclear.co.uk/research-peptides/tesamorelin/ [7] ema.europa.eu, https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-egrifta_en.pdf
